Taglich Brothers Initiates Coverage on Opexa Therapeutics, Inc.

NEW YORK, NY--(Marketwired - Sep 2, 2015) - Taglich Brothers, Inc. announces it initiated coverage of Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc. (NASDAQ: OPXA), headquartered in The Woodlands, Texas, aims to commercialize its personalized T-cell immunotherapy platform for autoimmune diseases, potentially developing multiple drug candidates tailored specifically for individual patients. The company's lead product candidate is Tcelna, now under study in a phase IIb trial as a treatment for secondary progressive multiple sclerosis (SPMS). That trial should be completed by mid-2016. If it proves sufficient Tcelna efficacy, the company will pursue a phase III trial and commercialization in the US and Europe through licensee Merck Serono.

OPXA is also developing OPX-212, a treatment for neuromyelitis optica, an autoimmune disorder in which immune system cells and antibodies mistakenly attack and destroy myelin cells in the optic nerves and the spinal cord. The company aims to complete preclinical work this year, potentially filing an Investigational New Study (IND) application by the end of 2015.

Tcelna is a T-cell-based personalized immunotherapy that is adapted to an individual patient's immune response to myelin, the fatty protective substance that covers the nerves in the brain and spinal cord. The immune system's myelin reactive T-cells' (MRTCs) assault on myelin degrades this protective covering and exposes the nerves to damage that impairs their ability to properly transmit signals to the rest of the body, leading to a range of disabilities. Tcelna consists of modified T-cell clones developed from T-cells drawn from a patient's own blood. Administered by subcutaneous injection, Tcelna triggers an immune system response directed at MRTCs, blocking or moderating their attacks on myelin.

The complete 14-page report is available at www.taglichbrothers.com.

We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report.

All research issued by Taglich Brothers, Inc. is based on public information. All research issued by Taglich Brothers, Inc. is based on public information. In September 2015 the company paid an initial monetary engagement fee of US$4,500 to Taglich Brothers, Inc. representing payment for the first three months of the creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$1,500 per month for such services for at least an additional three months.

For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.